Inclisiran是双链小干扰RNA（siRNA）分子，可抑制PCSK9转录，同时抑制焦亡、激活PPARγ，减少NLRP3、剪切型caspase-1、IL-1β、IL-18等炎症相关分子，具有抗炎、调节血脂、抗动脉粥样硬化活性，适用于高脂血症和心血管疾病（CVD）研究。

[1] Kong N, Xu Q, Cui W, Feng X, Gao H. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis. Ann Transl Med. 2022 Nov;10(22):1205. doi: 10.21037/atm-22-4652. PMID: 36544639; PMCID: PMC9761140.[2]Wang Z, Chen X, Liu J, Wang Y, Zhang S. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway. Autoimmunity. 2022 Jun;55(4):223-232. doi: 10.1080/08916934.2022.2051142. Epub 2022 Mar 15. PMID: 35289693.